Cumberland Pharmaceuticals, a Nashville, Tenn., specialty pharmaceutical company with a hodgepodge of acquired products, priced its IPO and now hopes to raise as much as $115 million. The company plans to offer 6.25 million shares, plus a possible overallotment of 937,000 additional shares, at a price between $14 and $16 apiece. The offering would value Cumberland at as much as $403 million.
Top Stories
- How badly could a recession hurt cleantech? ...
- Google prepping special iPhone ads?
- Stock market swings wildly -- plunges, then ...
- Orkut on the iPhone — a Brazilian ...
- Will Condé Nast close Portfolio? Magazines stay ...
Recent Guest Columnists
- William Quigley
Remaining objective when fear is in the air - Todd Kimmel
What to expect from cleantech in the downturn - Lee Hower
Platforms and developers, part three: What platforms like Facebook can do to expand the developer ecosystem
Job Board
- Product Manager
at True Knowledge (Cambridge, Cambridgeshire, UK) - Interactive Production Designer
at EyeWonder, Inc (233 Peachtree Street Atlanta, GA 30303) - Alliance Marketing Consultant BP
at Sun Microsystems (MENLO PARK, CA) - More Jobs » | Post a Job »
Links
Venturebeat Writers
- Matt Marshall, Editor-in-Chief
- Dean Takahashi, Lead Writer, DigitalMedia
- Eric Eldon, Editor, DigitalMedia
- MG Siegler, Writer, DigitalMedia
- Anthony Ha, Writer, VentureBeat
- Chris Morrison, Writer, CleanTech
- For advertising, contact .
- Log in
5:02 pm
VentureBeat » Amgen grabs the axe, chops up to 2,600 jobs said:
[...] will bring the first test in that regard: Cumberland Pharmaceuticals, which we noted briefly here, is due to launch its IPO sometime between now and [...]
1:26 pm
VentureBeat » Life sciences briefing: Friday, Sept. 21, 2007 said:
[...] At that, Zars is in far better shape than Cumberland Pharmaceuticals, which has been expected to go public on a day-to-day basis since mid-August. We last wrote about Cumberland here. [...]